Form 4: Replimune CFO Granted 60,000 RSUs in Equity Award

Replimune Group, Inc.'s Chief Financial Officer, Emily Luisa Hill, was granted 60,000 restricted stock units, vesting over two years.

Summary

• Emily Luisa Hill, Chief Financial Officer of Replimune Group, Inc., was granted 60,000 shares of the company's common stock.
• These shares represent Restricted Stock Units (RSUs) with a grant price of $0, meaning they are a contingent right to receive shares upon vesting.
• The RSUs are scheduled to vest in two equal tranches: 50% on November 15, 2026, and the remaining 50% on November 15, 2027.
• Vesting is contingent upon Ms. Hill's continuous service to Replimune Group, Inc.
• Following this transaction, Ms. Hill's beneficial ownership of common stock totals 194,368 shares.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: This is a routine executive compensation grant, generally viewed as positive for aligning management incentives with long-term company performance and retention. It does not, however, provide new operational or financial news that would significantly alter the company's immediate outlook.

Positives

• The grant of 60,000 Restricted Stock Units (RSUs) to the Chief Financial Officer aligns executive incentives with the long-term performance and shareholder value of Replimune Group, Inc.
• The multi-year vesting schedule (50% on November 15, 2026, and 50% on November 15, 2027) promotes the retention of key executive talent and encourages sustained commitment to the company's strategic goals.

Risks

• The vesting of the 60,000 Restricted Stock Units is subject to the Reporting Person's continuous service to Replimune Group, Inc., meaning the shares are not guaranteed if employment ceases before the vesting dates.

Future Outlook

The grant of Restricted Stock Units with a multi-year vesting schedule signals a commitment to retaining key executive talent and aligning their interests with the company's long-term performance and strategic objectives.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

Executive equity grants, particularly Restricted Stock Units, are a standard and widely adopted component of compensation packages across the biotechnology and pharmaceutical industries. These awards are designed to incentivize long-term performance, foster executive retention, and align management's financial interests with those of shareholders.

Comparison to Industry Standards

• The utilization of Restricted Stock Units (RSUs) as a compensation mechanism is a prevalent practice within the biotech and broader life sciences sectors, mirroring compensation strategies observed at comparable companies such as Moderna or Biogen for their senior executives.
• A two-year vesting schedule for executive equity awards, with tranches vesting annually, is typical for the industry, striking a balance between immediate incentive and long-term retention, consistent with practices at peer companies.
• The grant price of $0 for RSUs is standard, as these awards represent a right to receive shares upon the fulfillment of vesting conditions, rather than an option to purchase at a set price.

Stakeholder Impact

• **Shareholders:** Positive impact due to increased alignment of executive incentives with long-term company performance and the retention of key management personnel.
• **Employees:** May signal stability in executive leadership and a consistent approach to executive compensation practices within the company.

Next Steps

• Continued service of Emily Luisa Hill to Replimune Group, Inc. to meet the conditions for RSU vesting.
• Vesting of 50% of the granted RSUs on November 15, 2026.
• Vesting of the remaining 50% of the granted RSUs on November 15, 2027.

Key Dates

Recommendation

The grant of Restricted Stock Units to the Chief Financial Officer is a standard executive compensation practice aimed at aligning management's long-term interests with those of shareholders and retaining key talent. While this is a positive signal for corporate governance and executive retention, this routine transaction does not introduce new material information that would fundamentally alter the investment thesis for Replimune Group, Inc. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions based on broader company fundamentals rather than this specific compensation event.

Keywords

Replimune Group, REPL, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Emily Luisa Hill, CFO, Equity Grant, Stock Award